SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Alkem Laboratories - Quaterly Results

07 Nov 2023 Evaluate
The Revenue for the quarter ended  September 2023 of Rs. 26345.90 millions grew by 7.03 % from Rs. 24614.90 millions.Net profit for the quarter ended September 2023 increased significantly by 84.35% to Rs. 6465.10 millions from Rs. 3506.90 millions.OP of the company witnessed a marginal growth to 7164.40 millions from 4793.20 millions in the same quarter last year.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202309 202209 % Var 202309 202209 % Var 202303 202203 % Var
Sales 26345.90 24614.90 7.03 48877.60 45198.40 8.14 90545.50 88298.10 2.55
Other Income 618.40 736.40 -16.02 1265.40 1289.50 -1.87 2662.90 1998.90 33.22
PBIDT 7164.40 4793.20 49.47 11148.90 7179.40 55.29 16432.40 20102.50 -18.26
Interest 187.00 200.20 -6.59 401.20 420.40 -4.57 864.00 379.00 127.97
PBDT 6977.40 4593.00 51.91 10747.70 6759.00 59.01 15568.40 19723.50 -21.07
Depreciation 590.20 577.40 2.22 1171.30 1145.50 2.25 2298.50 2189.80 4.96
PBT 6387.20 4015.60 59.06 9576.40 5613.50 70.60 13269.90 17533.70 -24.32
TAX -77.90 508.70 -115.31 396.90 705.60 -43.75 1925.20 2121.20 -9.24
Deferred Tax -1192.70 -191.10 524.12 -1257.20 -269.30 366.84 -350.00 -917.00 -61.83
PAT 6465.10 3506.90 84.35 9179.50 4907.90 87.04 11344.70 15412.50 -26.39
Equity 239.10 239.10 0.00 239.10 239.10 0.00 239.10 239.10 0.00
PBIDTM(%) 27.19 19.47 39.65 22.81 15.88 43.60 18.15 22.77 -20.29

Alkem Laboratories Share Price

5583.70 16.00 (0.29%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×